Skip to content
DataLookout
Menu

NCT06770504

A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

StatusActive, Not Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 30, 2025 to Jun 30, 2027 Show 5 more changesShow less
    • Eligibility criteria expanded, about 25 words
    • Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Study completion pushed from Dec 30, 2026 to Dec 30, 2027
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 16, 2025 to Feb 26, 2025
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Dose Limiting Toxicity
Timeframe: Within 28 days after infusion
The incidence and frequency of treatment-emergent adverse events
Timeframe: Within 12 months after infusion
Best overall response rate (BOR) of each dose group
Timeframe: Within 12 weeks after infusion
Objective response rate (ORR) of each dose group
Timeframe: Within 4 weeks after infusion
Time to response (TTR)
Timeframe: Within 6 months after infusion

Arms and interventions

YTS109Experimental

Participants will receive YTS109 cell infusion after preconditioning, and they need to be closely monitored for 24 hours following START-T cell infusion.

Biologicals: YTS109

Sites

1 site in 1 country

  • Regenerative Medicine CenterTianjin, Tianjin Municipality, China